TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Acrux ( (AU:ACR) ) just unveiled an update.
Acrux Limited has received a $0.46 million advance from Radium Capital as part of its FY25 R&D Tax Incentive, bringing the total advances to $2.19 million. This funding provides early access to the RDTI rebate, which will support the development of products and management of working capital, highlighting Acrux’s strategic use of financial resources to bolster its operations.
More about Acrux
Acrux is a specialty pharmaceutical company that focuses on developing and commercializing topically applied pharmaceutical products. With 25 years of experience, Acrux has successfully marketed products worldwide, particularly in the United States. The company leverages its skilled workforce, on-site laboratories, and GMP manufacturing suite to formulate and develop affordable topical generic products. Acrux is open to collaboration and commercial partnerships for product development opportunities.
Average Trading Volume: 313,279
Technical Sentiment Signal: Sell
Current Market Cap: A$7.34M
Find detailed analytics on ACR stock on TipRanks’ Stock Analysis page.